Many brands rely on heavy and year-round discounts to stay competitive, only to find themselves trapped in shrinking margins and weakened brand perception
Behari J, Gougol A, Wang R, Luu HN, Paragomi P, Yu YC, et al
With the 12 mg dose, 39.4% of participants achieved at least 30% weight loss
Studies show that injection-site redness or itching occurs in a few percent of users
Both medications can lower appetite, slow stomach emptying, and regulate blood sugar , but tirzepatide mimics two hormones (GLP-1 and GIP ) while semaglutide mimics just GLP-1
dba Hers September 09, 2025 FDA, accessed February 8, 2026, FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs, accessed February 8, 2026, 2025 PBM Satisfaction: Navigating Change and Opportunity in Pharmacy Benefit Management | Pharmaceutical Strategies Group (PSG), accessed February 8, 2026, Unchecked power in PBM industry puts patients at risk of harm, accessed February 8, 2026, The Future of PBMs in 2025: AI, Regulations, and Transparency Initiatives | Pharmacy Times, accessed February 8, 2026, Pharmacy Benefit Management PBM Market Outlook 2025-2032, accessed February 8, 2026, HIMS vs